Department of Dermatology

Elizabeth Buzney, M.D. | James Campbell, Ph.D. | Rachael Clark, M.D., Ph.D. | Charles Dimitroff, Ph.D. |

Markus Frank, M.D. | Robert Fuhlbrigge, M.D., Ph.D. | Jiali Han, Ph.D. | Harley Haynes, M.D. |

Thomas Kupper, M.D. | Abrar Qureshi, M.D., M.P.H. | James Rheinwald, Ph.D. | Robert Sackstein, M.D., Ph.D. | 

Chrysalyne Schmults, M.D. | Linda Wang, M.D., J.D. | Andrew Werchniak, M.D. | Hans Widlund, Ph.D.

Elizabeth Buzney, M.D.

1. Buzney EA, Kimball AB: A critical assessment of composite and coprimary endpoints: a complex problem. J Am Acad Dermatol 2008, 59(5):890-896.

2. Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC: T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007, 13(9):2549-2556.

3. Zubovits J, Buzney E, Yu L, Duncan LM: HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol 2004, 35(2):217-223.

4. Lacy SE, Bonnemann CG, Buzney EA, Kunkel LM: Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins. Genomics 1999, 62(3):417-426.

James Campbell, Ph.D.

1. Morgan AJ, Guillen C, Symon FA, Birring SS, Campbell JJ, Wardlaw AJ: CXCR6 identifies a putative population of retained human lung T cells characterised by co-expression of activation markers. Immunobiology 2008, 213(7):599-608.

2. Wurbel MA, Malissen M, Guy-Grand D, Malissen B, Campbell JJ: Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J Immunol 2007, 178(12):7598-7606.

3. Meyer EH, Wurbel MA, Staton TL, Pichavant M, Kan MJ, Savage PB, DeKruyff RH, Butcher EC, Campbell JJ, Umetsu DT: iNKT cells require CCR4 to localize to the airways and to induce airway hyperreactivity. J Immunol 2007, 179(7):4661-4671.

4. Janowicz DM, Tenner-Racz K, Racz P, Humphreys TL, Schnizlein-Bick C, Fortney KR, Zwickl B, Katz BP, Campbell JJ, Ho DD et al: Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication. J Infect Dis 2007, 195(10):1443-1451.

5. Campbell JJ, O'Connell DJ, Wurbel MA: Cutting Edge: Chemokine receptor CCR4 is necessary for antigen-driven cutaneous accumulation of CD4 T cells under physiological conditions. J Immunol 2007, 178(6):3358-3362.

6. Wurbel MA, Malissen B, Campbell JJ: Complex regulation of CCR9 at multiple discrete stages of T cell development. Eur J Immunol 2006, 36(1):73-81.

7. Ni Z, Campbell JJ, Niehans G, Walcheck B: The monoclonal antibody CHO-131 identifies a subset of cutaneous lymphocyte-associated antigen T cells enriched in P-selectin-binding cells. J Immunol 2006, 177(7):4742-4748.

8. Kivisakk P, Tucky B, Wei T, Campbell JJ, Ransohoff RM: Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy. BMC Immunol 2006, 7:14.

9. Heydtmann M, Hardie D, Shields PL, Faint J, Buckley CD, Campbell JJ, Salmon M, Adams DH: Detailed analysis of intrahepatic CD8 T cells in the normal and hepatitis C-infected liver reveals differences in specific populations of memory cells with distinct homing phenotypes. J Immunol 2006, 177(1):729-738.

10. Humphreys TL, Baldridge LA, Billings SD, Campbell JJ, Spinola SM: Trafficking pathways and characterization of CD4 and CD8 cells recruited to the skin of humans experimentally infected with Haemophilus ducreyi. Infect Immun 2005, 73(7):3896-3902.

11. Baekkevold ES, Wurbel MA, Kivisakk P, Wain CM, Power CA, Haraldsen G, Campbell JJ: A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations. J Exp Med 2005, 201(7):1045-1051.

12. Soler D, Humphreys TL, Spinola SM, Campbell JJ: CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 2003, 101(5):1677-1682.

13. Kivisakk P, Trebst C, Lee JC, Tucky BH, Rudick RA, Campbell JJ, Ransohoff RM: Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals. J Neurovirol 2003, 9(3):291-299.

14. Kivisakk P, Mahad DJ, Callahan MK, Trebst C, Tucky B, Wei T, Wu L, Baekkevold ES, Lassmann H, Staugaitis SM et al: Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A 2003, 100(14):8389-8394.

15. Kivisakk P, Liu Z, Trebst C, Tucky B, Wu L, Stine J, Mack M, Rudick RA, Campbell JJ, Ransohoff RM: Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods 2003, 29(4):319-325.

16. Glodek AM, Honczarenko M, Le Y, Campbell JJ, Silberstein LE: Sustained activation of cell adhesion is a differentially regulated process in B lymphopoiesis. J Exp Med 2003, 197(4):461-473.

17. Boisvert J, Kunkel EJ, Campbell JJ, Keeffe EB, Butcher EC, Greenberg HB: Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol 2003, 38(1):67-75.

18. Kunkel EJ, Boisvert J, Murphy K, Vierra MA, Genovese MC, Wardlaw AJ, Greenberg HB, Hodge MR, Wu L, Butcher EC et al: Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 2002, 160(1):347-355.

19. Honczarenko M, Le Y, Glodek AM, Majka M, Campbell JJ, Ratajczak MZ, Silberstein LE: CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood 2002, 100(7):2321-2329.

20. Christopherson KW, 2nd, Campbell JJ, Travers JB, Hromas RA: Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther 2002, 302(1):290-295.

Rachael Clark, M.D., Ph.D.

1. Liu Y, Franco A, Huang L, Gersappe D, Clark RA, Rafailovich MH: Control of cell migration in two and three dimensions using substrate morphology. Exp Cell Res 2009.

2. Liu Y, Ji Y, Ghosh K, Clark RA, Huang L, Rafailovich MH: Effects of fiber orientation and diameter on the behavior of human dermal fibroblasts on electrospun PMMA scaffolds. J Biomed Mater Res A 2008.

3. Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, Schanbacher CF, Edwards V, Miller DM, Kim JE et al: Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008, 205(10):2221-2234.

4. Clark RA, Kupper TS: IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 2007, 109(1):194-202.

5. Clark RA, Fuhlbrigge RC: Meeting report of immunology and skin disease: new perspectives. J Invest Dermatol 2007, 127(8):1838-1841.

6. Yamanaka K, Clark R, Rich B, Dowgiert R, Hirahara K, Hurwitz D, Shibata M, Mirchandani N, Jones DA, Goddard DS et al: Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006, 107(6):2440-2445.

7. Yamanaka K, Clark R, Dowgiert R, Hurwitz D, Shibata M, Rich BE, Hirahara K, Jones DA, Eapen S, Mizutani H et al: Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 2006, 12(2):376-382.

8. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS: The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006, 177(7):4488-4494.

9. Clark RA, Kupper TS: Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 2006, 116(8):2084-2087.

10. Clark RA, Chong BF, Mirchandani N, Yamanaka K, Murphy GF, Dowgiert RK, Kupper TS: A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol 2006, 126(5):1059-1070.

11. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, Kupper TS: The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006, 176(7):4431-4439.

12. Clark RA, Yamanaka K, Bai M, Dowgiert R, Kupper TS: Human skin cells support thymus-independent T cell development. J Clin Invest 2005, 115(11):3239-3249.

13. Clark R, Kupper T: Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol 2005, 125(4):629-637.

14. Formica M, Kabbara K, Clark R, McAlindon T: Can clinical trials requiring frequent participant contact be conducted over the Internet? Results from an online randomized controlled trial evaluating a topical ointment for herpes labialis. J Med Internet Res 2004, 6(1):e6.

15. Clark RA, Fuhlbrigge RC, Springer TA: L-Selectin ligands that are O-glycoprotease resistant and distinct from MECA-79 antigen are sufficient for tethering and rolling of lymphocytes on human high endothelial venules. J Cell Biol 1998, 140(3):721-731.

16. Clark RA, Erickson HP, Springer TA: Tenascin supports lymphocyte rolling. J Cell Biol 1997, 137(3):755-765.

17. Clark RA, Alon R, Springer TA: CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma. J Cell Biol 1996, 134(4):1075-1087.

Charles Dimitroff, Ph.D.

1. Wiese G, Barthel SR, Dimitroff CJ: Analysis of physiologic E-selectin-mediated leukocyte rolling on microvascular endothelium. J Vis Exp 2009(24).

2. Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, Kakeda M, Kurokawa I, Mizutani H, Kupper TS: Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol 2008, 121(1):148-157 e143.

3. Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ: Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology 2008, 18(10):806-817.

4. Gainers ME, Descheny L, Barthel SR, Liu L, Wurbel MA, Dimitroff CJ: Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J Immunol 2007, 179(12):8509-8518.

5. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ: Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007, 11(11):1473-1491.

6. Alcaide P, King SL, Dimitroff CJ, Lim YC, Fuhlbrigge RC, Luscinskas FW: The 130-kDa glycoform of CD43 functions as an E-selectin ligand for activated Th1 cells in vitro and in delayed-type hypersensitivity reactions in vivo. J Invest Dermatol 2007, 127(8):1964-1972.

7. Descheny L, Gainers ME, Walcheck B, Dimitroff CJ: Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J Invest Dermatol 2006, 126(9):2065-2073.

8. Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA: Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res 2005, 65(13):5750-5760.

9. Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL: Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. Cancer Res 2004, 64(15):5261-5269.

10. Dimitroff CJ, Kupper TS, Sackstein R: Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003, 112(7):1008-1018.

11. Dimitroff CJ, Bernacki RJ, Sackstein R: Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 2003, 101(2):602-610.

12. Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R: Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. J Immunol 2002, 168(11):5645-5651.

13. Dimitroff CJ, Lee JY, Schor KS, Sandmaier BM, Sackstein R: differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1. J Biol Chem 2001, 276(50):47623-47631.

14. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R: CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001, 153(6):1277-1286.

15. Sackstein R, Dimitroff CJ: A hematopoietic cell L-selectin ligand that is distinct from PSGL-1 and displays N-glycan-dependent binding activity. Blood 2000, 96(8):2765-2774.

16. Dimitroff CJ, Lee JY, Fuhlbrigge RC, Sackstein R: A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci U S A 2000, 97(25):13841-13846.

17. Dimitroff CJ, Pera P, Dall'Olio F, Matta KL, Chandrasekaran EV, Lau JT, Bernacki RJ: Cell surface n-acetylneuraminic acid alpha2,3-galactoside-dependent intercellular adhesion of human colon cancer cells. Biochem Biophys Res Commun 1999, 256(3):631-636.

18. Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A et al: Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999, 17(2):121-135.

19. Dimitroff CJ, Sharma A, Bernacki RJ: Cancer metastasis: a search for therapeutic inhibition. Cancer Invest 1998, 16(4):279-290.

20. Woynarowska B, Dimitroff CJ, Sharma M, Matta KL, Bernacki RJ: Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue. Glycoconj J 1996, 13(4):663-674.

Markus Frank, M.D.

1. Frank NY, Frank MH: ABCB5 gene amplification in human leukemia cells. Leuk Res 2009.

2. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C et al: Identification of cells initiating human melanomas. Nature 2008, 451(7176):345-349.

3. Pendse SS, Behjati S, Schatton T, Izawa A, Sayegh MH, Frank MH: P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am J Transplant 2006, 6(12):2884-2893.

4. Frank NY, Kho AT, Schatton T, Murphy GF, Molloy MJ, Zhan Q, Ramoni MF, Frank MH, Kohane IS, Gussoni E: Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. J Cell Biol 2006, 175(1):99-110.

5. Lutz NW, Franks SE, Frank MH, Pomer S, Hull WE: Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays. MAGMA 2005, 18(3):144-161.

6. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH: ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65(10):4320-4333.

7. Lapchak PH, Melter M, Pal S, Flaxenburg JA, Geehan C, Frank MH, Mukhopadhyay D, Briscoe DM: CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island. Am J Physiol Renal Physiol 2004, 287(3):F512-520.

8. Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH, Frank MH: Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003, 278(47):47156-47165.

9. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM: Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 2001, 166(4):2451-2459.

10. Frank MH, Pomer S: Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype. J Cancer Res Clin Oncol 1999, 125(2):117-120.

Robert Fuhlbrigge, M.D., Ph.D.

1. Tian T, Liu L, Freyschmidt EJ, Murphy GF, Kupper TS, Fuhlbrigge RC: Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus. J Invest Dermatol 2009, 129(1):70-78.

2. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP: Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009, 60(6):1825-1830.

3. Bianchi T, Pincus LB, Wurbel MA, Rich BE, Kupper TS, Fuhlbrigge RC, Boes M: Maintenance of peripheral tolerance through controlled tissue homing of antigen-specific T cells in K14-mOVA mice. J Immunol 2009, 182(8):4665-4674.

4. Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, Kakeda M, Kurokawa I, Mizutani H, Kupper TS: Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol 2008, 121(1):148-157 e143.

5. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C et al: Identification of cells initiating human melanomas. Nature 2008, 451(7176):345-349.

6. Ota S, Cron RQ, Schanberg LE, O'Neil K, Mellins ED, Fuhlbrigge RC, Feldman BM: Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus. Pediatr Rheumatol Online J 2008, 6:5.

7. Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC: T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007, 13(9):2549-2556.

8. Fuhlbrigge RC, Weishaupt C: Adhesion molecules in cutaneous immunity. Semin Immunopathol 2007, 29(1):45-57.

9. El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP: Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 2007, 150(4):376-382.

10. Clark RA, Fuhlbrigge RC: Meeting report of immunology and skin disease: new perspectives. J Invest Dermatol 2007, 127(8):1838-1841.

11. Alcaide P, King SL, Dimitroff CJ, Lim YC, Fuhlbrigge RC, Luscinskas FW: The 130-kDa glycoform of CD43 functions as an E-selectin ligand for activated Th1 cells in vitro and in delayed-type hypersensitivity reactions in vivo. J Invest Dermatol 2007, 127(8):1964-1972.

12. Liu L, Fuhlbrigge RC, Karibian K, Tian T, Kupper TS: Dynamic programming of CD8+ T cell trafficking after live viral immunization. Immunity 2006, 25(3):511-520.

13. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS: The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006, 177(7):4488-4494.

14. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E et al: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355(6):581-592.

15. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS: CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006, 107(4):1421-1426.

16. Liu L, Xu Z, Fuhlbrigge RC, Pena-Cruz V, Lieberman J, Kupper TS: Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. J Virol 2005, 79(12):7363-7370.

17. Binstadt BA, Levine JC, Nigrovic PA, Gauvreau K, Dedeoglu F, Fuhlbrigge RC, Weindling SN, Newburger JW, Sundel RP: Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics 2005, 116(1):e89-93.

18. Kupper TS, Fuhlbrigge RC: Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4(3):211-222.

19. Chong BF, Murphy JE, Kupper TS, Fuhlbrigge RC: E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J Immunol 2004, 172(3):1575-1581.

20. Nigrovic PA, Fuhlbrigge RC, Sundel RP: Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics 2003, 111(4 Pt 1):715-721.

21. Binstadt BA, Caldas AM, Turvey SE, Stone KD, Weinstein HJ, Jackson J, Fuhlbrigge RC, Sundel RP: Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 2003, 143(5):598-604.

22. Pendl GG, Robert C, Steinert M, Thanos R, Eytner R, Borges E, Wild MK, Lowe JB, Fuhlbrigge RC, Kupper TS et al: Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. Blood 2002, 99(3):946-956.

23. Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R: Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. J Immunol 2002, 168(11):5645-5651.

24. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002, 47(4):505-511.

25. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS: Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002, 119(6):1405-1410.

26. Kieffer JD, Fuhlbrigge RC, Armerding D, Robert C, Ferenczi K, Camphausen RT, Kupper TS: Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. Biochem Biophys Res Commun 2001, 285(3):577-587.

27. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R: CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001, 153(6):1277-1286.

28. Armerding D, Fuhlbrigge RC, Kieffer JD, Kupper TS: Tonsillar B cells do not express PSGL-1, but a significant fraction displays the cutaneous lymphocyte antigen and exhibits effective E- and P-selectin ligand activity. Int Arch Allergy Immunol 2001, 126(1):78-90.

29. Eberhard BA, Sundel RP, Newburger JW, Baker A, Fuhlbrigge RC, Burns JC, Gellis SE: Psoriatic eruption in Kawasaki disease. J Pediatr 2000, 137(4):578-580.

30. Dimitroff CJ, Lee JY, Fuhlbrigge RC, Sackstein R: A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci U S A 2000, 97(25):13841-13846.

31. Carcamo AS, Fuhlbrigge RC, Hong R, Gullans SR, Kupper TS: Comparative analysis of the global transcriptional profile of human skin-homing memory T lymphocytes vs. non-skin homing memory and naive T lymphocytes. J Invest Dermatol 2000, 115(2):332.

32. Robert C, Fuhlbrigge RC, Kieffer JD, Ayehunie S, Hynes RO, Cheng G, Grabbe S, von Andrian UH, Kupper TS: Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance. J Exp Med 1999, 189(4):627-636.

33. Clark RA, Fuhlbrigge RC, Springer TA: L-Selectin ligands that are O-glycoprotease resistant and distinct from MECA-79 antigen are sufficient for tethering and rolling of lymphocytes on human high endothelial venules. J Cell Biol 1998, 140(3):721-731.

34. Kitayama J, Fuhlbrigge RC, Puri KD, Springer TA: P-selectin, L-selectin, and alpha 4 integrin have distinct roles in eosinophil tethering and arrest on vascular endothelial cells under physiological flow conditions. J Immunol 1997, 159(8):3929-3939.

35. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS: Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997, 389(6654):978-981.

36. Chen S, Alon R, Fuhlbrigge RC, Springer TA: Rolling and transient tethering of leukocytes on antibodies reveal specializations of selectins. Proc Natl Acad Sci U S A 1997, 94(7):3172-3177.

37. Fuhlbrigge RC, Alon R, Puri KD, Lowe JB, Springer TA: Sialylated, fucosylated ligands for L-selectin expressed on leukocytes mediate tethering and rolling adhesions in physiologic flow conditions. J Cell Biol 1996, 135(3):837-848.

38. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996, 184(3):1101-1109.

39. Alon R, Fuhlbrigge RC, Finger EB, Springer TA: Interactions through L-selectin between leukocytes and adherent leukocytes nucleate rolling adhesions on selectins and VCAM-1 in shear flow. J Cell Biol 1996, 135(3):849-865.

40. Alon R, Feizi T, Yuen CT, Fuhlbrigge RC, Springer TA: Glycolipid ligands for selectins support leukocyte tethering and rolling under physiologic flow conditions. J Immunol 1995, 154(10):5356-5366.

41. Hawrylowicz CM, Duncan LM, Fuhlbrigge RC, Unanue ER: Regulation of antigen presentation. II. Anti-Ig and IL-2 induce IL-1 production by murine splenic B cells. J Immunol 1989, 142(10):3361-3368.

42. Fuhlbrigge RC, Hogquist KA, Unanue ER, Chaplin DD: Molecular biology and genetics of interleukin-1. Year Immunol 1989, 5:21-37.

43. Fuhlbrigge RC, Sheehan KC, Schreiber RD, Chaplin DD, Unanue ER: Monoclonal antibodies to murine IL-1 alpha. Production, characterization, and inhibition of membrane-associated IL-1 activity. J Immunol 1988, 141(8):2643-2650.

44. Fuhlbrigge RC, Fine SM, Unanue ER, Chaplin DD: Expression of membrane interleukin 1 by fibroblasts transfected with murine pro-interleukin 1 alpha cDNA. Proc Natl Acad Sci U S A 1988, 85(15):5649-5653.

45. Unanue ER, Weaver CT, Fuhlbrigge RC, Kiely JM, Chaplin DD: Membrane IL-1: a key protein in antigen presentation. Ann Inst Pasteur Immunol 1987, 138(3):489-492.

46. Fuhlbrigge RC, Chaplin DD, Kiely JM, Unanue ER: Regulation of interleukin 1 gene expression by adherence and lipopolysaccharide. J Immunol 1987, 138(11):3799-3802.

47. D'Eustachio P, Jadidi S, Fuhlbrigge RC, Gray PW, Chaplin DD: Interleukin-1 alpha and beta genes: linkage on chromosome 2 in the mouse. Immunogenetics 1987, 26(6):339-343.

48. Edwards BS, Fuhlbrigge RC, Borden EC: Separation of human natural killer cell subpopulations differentially responsive to interferon potentiation. J Interferon Res 1986, 6(4):361-372.

49. Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC: Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 1985, 75(6):1908-1913.

50. Fuhlbrigge RC, Edwards BS, Borden EC: Effects of interferon alpha on the sheep erythrocyte "receptor" of human lymphocytes. J Interferon Res 1984, 4(4):499-505.

Jiali Han, Ph.D.

1. Nan H, Qureshi AA, Hunter DJ, Han J: A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control 2009, 20(2):171-179.

2. Nan H, Qureshi AA, Hunter DJ, Han J: Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study. BMC Cancer 2009, 9:172.

3. Nan H, Kraft P, Qureshi AA, Guo Q, Chen C, Hankinson SE, Hu FB, Thomas G, Hoover RN, Chanock S et al: Genome-Wide Association Study of Tanning Phenotype in a Population of European Ancestry. J Invest Dermatol 2009.

4. Nan H, Kraft P, Hunter DJ, Han J: Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009, 125(4):909-917.

5. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J: A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 2009, 113(3):585-594.

6. Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ, De Vivo I: A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009, 129(2):415-421.

7. Han J, Haiman C, Niu T, Guo Q, Cox DG, Willett WC, Hankinson SE, Hunter DJ: Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk. Breast Cancer Res Treat 2009, 115(3):613-622.

8. Gu F, Qureshi AA, Kraft P, Guo Q, Hunter DJ, Han J: Polymorphisms in genes involved in DNA repair, cell growth, oxidative stress and inflammatory response, and melanoma risk. Br J Dermatol 2009, 161(1):209-212.

9. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A: Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 2009, 65(1):76-82.

10. Nan H, Qureshi AA, Hunter DJ, Han J: Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. Br J Dermatol 2008, 159(2):314-321.

11. Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A, Hankinson SE, Hu FB, Duffy DL, Zhao ZZ et al: A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008, 4(5):e1000074.

12. Haiman CA, Hsu C, de Bakker PI, Frasco M, Sheng X, Van Den Berg D, Casagrande JT, Kolonel LN, Le Marchand L, Hankinson SE et al: Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations. Hum Mol Genet 2008, 17(6):825-834.

13. Gu F, Qureshi AA, Niu T, Kraft P, Guo Q, Hunter DJ, Han J: Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res 2008, 18(5):330-335.

14. Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP, Sr., Qin Q et al: Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma. Am J Epidemiol 2007, 165(11):1255-1264.

15. Han J, Colditz GA, Hunter DJ: Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis 2007, 28(2):390-397.

16. Han J, Colditz GA, Hunter DJ: Manganese superoxide dismutase polymorphism and risk of skin cancer (United States). Cancer Causes Control 2007, 18(1):79-89.

17. Bugni JM, Han J, Tsai MS, Hunter DJ, Samson LD: Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst) 2007, 6(8):1116-1126.

18. Han J, Tranah GJ, Hankinson SE, Samson LD, Hunter DJ: Polymorphisms in O6-methylguanine DNA methyltransferase and breast cancer risk. Pharmacogenet Genomics 2006, 16(7):469-474.

19. Han J, Kraft P, Colditz GA, Wong J, Hunter DJ: Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006, 119(8):1976-1984.

20. Han J, Hankinson SE, De Vivo I: Polymorphisms in O6-methylguanine DNA methyltransferase and endometrial cancer risk. Carcinogenesis 2006, 27(11):2281-2285.

21. Han J, Cox DG, Colditz GA, Hunter DJ: The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog 2006, 45(9):694-700.

22. Han J, Colditz GA, Hunter DJ: Lack of associations of selected variants in genes involved in cell cycle and apoptosis with skin cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15(3):592-593.

23. Han J, Colditz GA, Hunter DJ: Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study. Int J Epidemiol 2006, 35(6):1514-1521.

24. Han J, Colditz GA, Liu JS, Hunter DJ: Genetic variation in XPD, sun exposure, and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(6):1539-1544.

25. Han J, Hankinson SE, Zhang SM, De Vivo I, Hunter DJ: Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004, 13(4):520-524.

26. Han J, Hankinson SE, Ranu H, De Vivo I, Hunter DJ: Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study. Carcinogenesis 2004, 25(2):189-195.

27. Han J, Hankinson SE, Hunter DJ, De Vivo I: Genetic variations in XRCC2 and XRCC3 are not associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2004, 13(2):330-331.

28. Han J, Hankinson SE, Colditz GA, Hunter DJ: Genetic variation in XRCC1, sun exposure, and risk of skin cancer. Br J Cancer 2004, 91(8):1604-1609.

29. Han J, Colditz GA, Samson LD, Hunter DJ: Polymorphisms in DNA double-strand break repair genes and skin cancer risk. Cancer Res 2004, 64(9):3009-3013.

30. Han J, Hankinson SE, De Vivo I, Spiegelman D, Tamimi RM, Mohrenweiser HW, Colditz GA, Hunter DJ: A prospective study of XRCC1 haplotypes and their interaction with plasma carotenoids on breast cancer risk. Cancer Res 2003, 63(23):8536-8541.

31. Han J, Hankinson SE, De Vivo I, Colditz GA, Hunter DJ: No association between a stop codon polymorphism in RAD52 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11(10 Pt 1):1138-1139.

Harley Haynes, M.D.

1. Turner RB, Haynes HA, Granter SR, Miller DM: Acquired cutis laxa following urticarial vasculitis associated with IgA myeloma. J Am Acad Dermatol 2009, 60(6):1052-1057.

2. Thieu KP, Haynes HA: Generalized essential telangiectasia with predilection for surgical scar. J Am Acad Dermatol 2009, 60(4):710-711.

3. Hu S, Granter SR, Haynes HA, Miller DM: Skin spicules: A newly described paraneoplastic phenomenon associated with a marginal zone B-cell lymphoma. J Am Acad Dermatol 2009, 60(5):852-855.

4. Haskell HD, Haynes HA, McKee PH, Redston M, Granter SR, Lazar AJ: Basal cell carcinoma with matrical differentiation: a case study with analysis of beta-catenin. J Cutan Pathol 2005, 32(3):245-250.

5. Turner RB, Kim CC, Streams BN, Culpepper K, Haynes HA: Anticonvulsant hypersensitivity syndrome associated with Bellamine S, a therapy for menopausal symptoms. J Am Acad Dermatol 2004, 50(5 Suppl):S86-89.

6. Chang HY, Wong KM, Bosenberg M, McKee PH, Haynes HA: Myelogenous leukemia cutis resembling stasis dermatitis. J Am Acad Dermatol 2003, 49(1):128-129.

7. Bradley VR, Liu V, Haynes HA: Rash with regional lymphadenopathy. Arch Dermatol 2003, 139(8):1075-1080.

8. Herbst A, Haynes HA, Nghiem P: The standard of care for Merkel cell carcinoma should include adjuvant radiation and lymph node surgery. J Am Acad Dermatol 2002, 46(4):640-642.

9. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG et al: Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J 2000, 6(3):139-145.

10. Li VW, Jaffe MP, Li WW, Haynes HA: Off-label dermatologic therapies. Usage, risks, and mechanisms. Arch Dermatol 1998, 134(11):1449-1454.

11. Haynes HA: What do medical students need and what do they want? Arch Dermatol 1998, 134(6):731-732.

12. Tsao H, Busam K, Barnhill RL, Haynes HA: Lesions resembling malignant atrophic papulosis in a patient with dermatomyositis. J Am Acad Dermatol 1997, 36(2 Pt 2):317-319.

13. Sharpe RJ, Albert LS, Imber MJ, Haynes HA: Isolation of viable virus from a patient with atypical measles and rash in an inverse photodistribution. J Am Acad Dermatol 1990, 22(6 Pt 1):1107-1109.

14. Horan RF, Tahan SR, Margolis RJ, Haynes HA: Atypical angiomatosis in polyarteritis nodosa. Br J Dermatol 1986, 115(5):611-618.

15. Horan RF, Kerdel FA, Moschella SL, Haynes HA: Recent onset of gingival enlargement. Arch Dermatol 1986, 122(12):1436, 1438-1439.

16. Kerdel FA, Fraker DL, Haynes HA: Necrotizing vasculitis from radiographic contrast media. J Am Acad Dermatol 1984, 10(1):25-29.

17. Haynes HA, Bernhard JD, Gange RW: Actinic reticuloid. Response to combination treatment with azathioprine, hydroxychloroquine, and prednisone. J Am Acad Dermatol 1984, 10(6):947-952.

18. Granstein RD, Soter NA, Haynes HA: Necrotizing vasculitis within cutaneous lesions of mycosis fungoides. J Am Acad Dermatol 1983, 9(1):128-133.

19. Bernhard JD, Haynes HA: Nonrashes. Part I: The Koebner nonreaction. Cutis 1982, 29(2):158-164.

20. Fine JD, Miller JA, Harrist TJ, Haynes HA: Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum. Am J Med 1981, 70(5):1133-1135.

21. Haynes HA: Mycosis fungoides. Clin Haematol 1979, 8(3):685-698.

22. Sober AJ, Haynes HA: Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol 1978, 114(3):439-441.

23. McLean DI, Haynes HA, McCarthy PL, Baden HP: Cryotherapy of basal-cell carcinoma by a simple method of standardized freeze-thaw cycles. J Dermatol Surg Oncol 1978, 4(2):175-177.

24. Tanenbaum L, Parrish JA, Haynes HA, Fitzpatrick TB, Pathak MA: Prolonged ultraviolet light-induced erythema and the cutaneous carcinoma phenotype. J Invest Dermatol 1976, 67(4):513-517.

25. Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB: Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976, 38(2):683-689.

26. Young RC, Corder MP, Haynes HA, DeVita VT: Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am J Med 1972, 52(1):63-72.

27. Murphy RL, Jr., Fitzpatrick TB, Haynes HA, Bird KT, Sheridan TB: Accuracy of dermatologic diagnosis by television. Arch Dermatol 1972, 105(6):833-835.

28. Haynes HA, Van Scott EJ: Therapy of mycosis fungoides lymphoma. Proc Natl Cancer Conf 1970, 6:553-557.

29. Block JB, Haynes HA, Thompson WL, Neiman PE: Delayed hypersensitivity in chronic lymphocytic leukemia. J Natl Cancer Inst 1969, 42(6):973-980.

30. Waldorf DS, Haynes HA, Van Scott EJ: Cutaneous hypersensitivity and desensitization to mechlorethamine in patients with mycosis fungoides lymphoma. Ann Intern Med 1967, 67(2):282-290.

31. Perry S, Thomas LB, Johnson RE, Carbone PP, Haynes HA: Hodgkin's disease. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1967, 67(2):424-442.

32. Brown RS, Haynes HA, Foley HT, Godwin HA, Berard CW, Carbone PP: Hodgkin's disease. Immunologic, clinical, and histologic features of 50 untreated patients. Ann Intern Med 1967, 67(2):291-302.

33. Berlin NI, Van Scott EJ, Clendenning WE, Archard HO, Block JB, Witkop CJ, Haynes HA: Basal cell nevus syndrome. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1966, 64(2):403-421.

Thomas Kupper, M.D.

1. Tian T, Liu L, Freyschmidt EJ, Murphy GF, Kupper TS, Fuhlbrigge RC: Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus. J Invest Dermatol 2009, 129(1):70-78.

2. Bianchi T, Pincus LB, Wurbel MA, Rich BE, Kupper TS, Fuhlbrigge RC, Boes M: Maintenance of peripheral tolerance through controlled tissue homing of antigen-specific T cells in K14-mOVA mice. J Immunol 2009, 182(8):4665-4674.

3. Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, Kakeda M, Kurokawa I, Mizutani H, Kupper TS: Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol 2008, 121(1):148-157 e143.

4. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C et al: Identification of cells initiating human melanomas. Nature 2008, 451(7176):345-349.

5. Kimball AB, Kupper TS: Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. Clin Dermatol 2008, 26(5):554-561.

6. Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, Schanbacher CF, Edwards V, Miller DM, Kim JE et al: Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008, 205(10):2221-2234.

7. Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC: T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007, 13(9):2549-2556.

8. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, Kupper TS: Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007, 110(8):3015-3027.

9. Clark RA, Kupper TS: IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 2007, 109(1):194-202.

10. Yamanaka K, Clark R, Rich B, Dowgiert R, Hirahara K, Hurwitz D, Shibata M, Mirchandani N, Jones DA, Goddard DS et al: Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006, 107(6):2440-2445.

11. Yamanaka K, Clark R, Dowgiert R, Hurwitz D, Shibata M, Rich BE, Hirahara K, Jones DA, Eapen S, Mizutani H et al: Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 2006, 12(2):376-382.

12. Liu L, Fuhlbrigge RC, Karibian K, Tian T, Kupper TS: Dynamic programming of CD8+ T cell trafficking after live viral immunization. Immunity 2006, 25(3):511-520.

13. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS: The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006, 177(7):4488-4494.

14. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS: CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006, 107(4):1421-1426.

15. Figueiredo ML, Dayan S, Kim Y, McBride J, Kupper TS, Wong DT: Expression of cell-cycle regulator CDK2-associating protein 1 (p12CDK2AP1) in transgenic mice induces testicular and ovarian atrophy in vivo. Mol Reprod Dev 2006, 73(8):987-997.

16. Clark RA, Kupper TS: Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 2006, 116(8):2084-2087.

17. Clark RA, Chong BF, Mirchandani N, Yamanaka K, Murphy GF, Dowgiert RK, Kupper TS: A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol 2006, 126(5):1059-1070.

18. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, Kupper TS: The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006, 176(7):4431-4439.

19. Yamanaka K, Yawalkar N, Jones DA, Hurwitz D, Ferenczi K, Eapen S, Kupper TS: Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma. Clin Cancer Res 2005, 11(16):5748-5755.

20. Yamanaka K, Inaba T, Nomura E, Hurwitz D, Jones DA, Hakamada A, Isoda K, Kupper TS, Mizutani H: Basic fibroblast growth factor treatment for skin ulcerations in scleroderma. Cutis 2005, 76(6):373-376.

21. Mee JB, Antonopoulos C, Poole S, Kupper TS, Groves RW: Counter-regulation of interleukin-1alpha (IL-1alpha) and IL-1 receptor antagonist in murine keratinocytes. J Invest Dermatol 2005, 124(6):1267-1274.

22. Liu L, Xu Z, Fuhlbrigge RC, Pena-Cruz V, Lieberman J, Kupper TS: Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. J Virol 2005, 79(12):7363-7370.

23. Inaba T, Yamanaka K, Asahi K, Omoto Y, Isoda K, Hurwitz D, Kupper TS, Mizutani H: Complete remission in a patient with angiosarcoma by the combination of OK-432, rhIL-2, and radiotherapy. Eur J Dermatol 2005, 15(5):411-413.

24. Goddard DS, Yamanaka K, Kupper TS, Jones DA: Activation of neutrophils in cutaneous T-cell lymphoma. Clin Cancer Res 2005, 11(23):8243-8249.

25. Clark RA, Yamanaka K, Bai M, Dowgiert R, Kupper TS: Human skin cells support thymus-independent T cell development. J Clin Invest 2005, 115(11):3239-3249.

26. Kupper TS, Fuhlbrigge RC: Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4(3):211-222.

27. Jones DA, Yawalkar N, Suh KY, Sadat S, Rich B, Kupper TS: Identification of autoantigens in psoriatic plaques using expression cloning. J Invest Dermatol 2004, 123(1):93-100.

28. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, Kupper TS, Burakoff SJ: Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biol Blood Marrow Transplant 2004, 10(7):448-460.

29. Dayan S, Stashenko P, Niederman R, Kupper TS: Oral epithelial overexpression of IL-1alpha causes periodontal disease. J Dent Res 2004, 83(10):786-790.

30. Chong BF, Murphy JE, Kupper TS, Fuhlbrigge RC: E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J Immunol 2004, 172(3):1575-1581.

31. Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS: Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol 2004, 51(4):660-662.

32. Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, Kupper TS: Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003, 102(12):4059-4066.

33. Robert C, Klein C, Cheng G, Kogan A, Mulligan RC, von Andrian UH, Kupper TS: Gene therapy to target dendritic cells from blood to lymph nodes. Gene Ther 2003, 10(17):1479-1486.

34. Murphy JE, Morales RE, Scott J, Kupper TS: IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. J Immunol 2003, 170(11):5697-5703.

35. Kupper TS: Immunologic targets in psoriasis. N Engl J Med 2003, 349(21):1987-1990.

36. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS, Stingl G: IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol 2003, 170(11):5438-5444.

37. Hurwitz DJ, Pincus L, Kupper TS: Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 2003, 139(10):1347-1350.

38. Ferenczi K, Yawalkar N, Jones D, Kupper TS: Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy. Arch Dermatol 2003, 139(7):909-913.

39. Dimitroff CJ, Kupper TS, Sackstein R: Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003, 112(7):1008-1018.

40. Pendl GG, Robert C, Steinert M, Thanos R, Eytner R, Borges E, Wild MK, Lowe JB, Fuhlbrigge RC, Kupper TS et al: Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. Blood 2002, 99(3):946-956.

41. Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R: Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. J Immunol 2002, 168(11):5645-5651.

42. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS: Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002, 119(6):1405-1410.

43. Rossiter H, Beissert S, Mayer C, Schon MP, Wienrich BG, Tschachler E, Kupper TS: Targeted expression of bcl-2 to murine basal epidermal keratinocytes results in paradoxical retardation of ultraviolet- and chemical-induced tumorigenesis. Cancer Res 2001, 61(9):3619-3626.

44. Rich BE, Kupper TS: Cytokines: IL-20 - a new effector in skin inflammation. Curr Biol 2001, 11(13):R531-534.

45. Kopp T, Kieffer JD, Rot A, Strommer S, Stingl G, Kupper TS: Inflammatory skin disease in K14/p40 transgenic mice: evidence for interleukin-12-like activities of p40. J Invest Dermatol 2001, 117(3):618-626.

46. Kieffer JD, Fuhlbrigge RC, Armerding D, Robert C, Ferenczi K, Camphausen RT, Kupper TS: Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. Biochem Biophys Res Commun 2001, 285(3):577-587.

47. Armerding D, Fuhlbrigge RC, Kieffer JD, Kupper TS: Tonsillar B cells do not express PSGL-1, but a significant fraction displays the cutaneous lymphocyte antigen and exhibits effective E- and P-selectin ligand activity. Int Arch Allergy Immunol 2001, 126(1):78-90.

48. Yamanaka K, Tanaka M, Tsutsui H, Kupper TS, Asahi K, Okamura H, Nakanishi K, Suzuki M, Kayagaki N, Black RA et al: Skin-specific caspase-1-transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J Immunol 2000, 165(2):997-1003.

49. Murphy JE, Robert C, Kupper TS: Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol 2000, 114(3):602-608.

50. Muller-Rover S, Rossiter H, Paus R, Handjiski B, Peters EM, Murphy JE, Mecklenburg L, Kupper TS: Overexpression of Bcl-2 protects from ultraviolet B-induced apoptosis but promotes hair follicle regression and chemotherapy-induced alopecia. Am J Pathol 2000, 156(4):1395-1405.

51. Kupper TS: T cells, immunosurveillance, and cutaneous immunity. J Dermatol Sci 2000, 24 Suppl 1:S41-45.

52. Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH: A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol 2000, 136(2):179-184.

53. Carcamo AS, Fuhlbrigge RC, Hong R, Gullans SR, Kupper TS: Comparative analysis of the global transcriptional profile of human skin-homing memory T lymphocytes vs. non-skin homing memory and naive T lymphocytes. J Invest Dermatol 2000, 115(2):332.

54. Robert C, Kupper TS: Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999, 341(24):1817-1828.

55. Robert C, Fuhlbrigge RC, Kieffer JD, Ayehunie S, Hynes RO, Cheng G, Grabbe S, von Andrian UH, Kupper TS: Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance. J Exp Med 1999, 189(4):627-636.

56. Muller-Rover S, Rossiter H, Lindner G, Peters EM, Kupper TS, Paus R: Hair follicle apoptosis and Bcl-2. J Investig Dermatol Symp Proc 1999, 4(3):272-277.

57. Armerding D, Kupper TS: Functional cutaneous lymphocyte antigen can be induced in essentially all peripheral blood T lymphocytes. Int Arch Allergy Immunol 1999, 119(3):212-222.

58. Rauschmayr-Kopp T, Williams IR, Borriello F, Sharpe AH, Kupper TS: Distinct roles for B7 costimulation in contact hypersensitivity and humoral immune responses to epicutaneous antigen. Eur J Immunol 1998, 28(12):4221-4227.

59. Mizutani H, Ohmoto Y, Kupper TS, Shimizu M: Endogenous neutralizing anti-IL-1 alpha autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed epidermal IL-1. J Dermatol Sci 1998, 20(1):63-71.

60. Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, Clark EA, Nadler LM: The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol 1998, 161(6):2708-2715.

61. Dubin DB, Hurowitz JC, Brettler D, Bernhard JD, Kadin ME, Wallace JE, Woda B, Pihan G, Kupper TS, Harrist TJ: Adnexotropic T-cell lymphoma presenting with generalized anhidrosis, progressive alopecia, pruritus, and Sjogren's syndrome. J Am Acad Dermatol 1998, 38(3):493-497.

62. Williams IR, Rawson EA, Manning L, Karaoli T, Rich BE, Kupper TS: IL-7 overexpression in transgenic mouse keratinocytes causes a lymphoproliferative skin disease dominated by intermediate TCR cells: evidence for a hierarchy in IL-7 responsiveness among cutaneous T cells. J Immunol 1997, 159(6):3044-3056.

63. Rossiter H, Alon R, Kupper TS: Selectins, T-cell rolling and inflammation. Mol Med Today 1997, 3(5):214-222.

64. Rauschmayr T, Groves RW, Kupper TS: Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci U S A 1997, 94(11):5814-5819.

65. Mizutani H, Ohyanagi S, Umeda Y, Shimizu M, Kupper TS: Loss of cutaneous delayed hypersensitivity reactions in nevus anemicus. Evidence for close concordance of cutaneous delayed hypersensitivity and endothelial E-selectin expression. Arch Dermatol 1997, 133(5):617-620.

66. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS: Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997, 389(6654):978-981.

67. Ayehunie S, Garcia-Zepeda EA, Hoxie JA, Horuk R, Kupper TS, Luster AD, Ruprecht RM: Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors. Blood 1997, 90(4):1379-1386.

68. Williams IR, Ort RJ, Daley D, Manning L, Karaoli T, Barnhill RL, Kupper TS: Constitutive expression of B7-1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas. J Immunol 1996, 156(9):3382-3388.

69. Williams IR, Kupper TS: Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci 1996, 58(18):1485-1507.

70. Kupper TS: The utility of transgenic mouse models in the study of cutaneous immunology and inflammation. J Dermatol 1996, 23(11):741-745.

71. Groves RW, Rauschmayr T, Nakamura K, Sarkar S, Williams IR, Kupper TS: Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease. J Clin Invest 1996, 98(2):336-344.

72. Compton CC, Kupper TS, Nadire KB: HIV-infected Langerhans cells constitute a significant proportion of the epidermal Langerhans cell population throughout the course of HIV disease. J Invest Dermatol 1996, 107(6):822-826.

73. Nakamura K, Williams IR, Kupper TS: Keratinocyte-derived monocyte chemoattractant protein 1 (MCP-1): analysis in a transgenic model demonstrates MCP-1 can recruit dendritic and Langerhans cells to skin. J Invest Dermatol 1995, 105(5):635-643.

74. Kupper TS, Groves RW: The interleukin-1 axis and cutaneous inflammation. J Invest Dermatol 1995, 105(1 Suppl):62S-66S.

75. Kupper TS: Adhesion molecules in scleroderma: collagen binding integrins. Int Rev Immunol 1995, 12(2-4):217-225.

76. Kieffer JD, Plopper G, Ingber DE, Hartwig JH, Kupper TS: Direct binding of F actin to the cytoplasmic domain of the alpha 2 integrin chain in vitro. Biochem Biophys Res Commun 1995, 217(2):466-474.

77. Groves RW, Mizutani H, Kieffer JD, Kupper TS: Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. Proc Natl Acad Sci U S A 1995, 92(25):11874-11878.

78. Groves RW, Giri J, Sims J, Dower SK, Kupper TS: Inducible expression of type 2 IL-1 receptors by cultured human keratinocytes. Implications for IL-1-mediated processes in epidermis. J Immunol 1995, 154(8):4065-4072.

79. Ayehunie S, Groves RW, Bruzzese AM, Ruprecht RM, Kupper TS, Langhoff E: Acutely infected Langerhans cells are more efficient than T cells in disseminating HIV type 1 to activated T cells following a short cell-cell contact. AIDS Res Hum Retroviruses 1995, 11(8):877-884.

80. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, Springer TA, Gutierrez-Ramos JC: Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 1994, 180(1):95-109.

81. Williams IR, Ort RJ, Kupper TS: Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc Natl Acad Sci U S A 1994, 91(26):12780-12784.

82. Williams IR, Kupper TS: Epidermal expression of intercellular adhesion molecule 1 is not a primary inducer of cutaneous inflammation in transgenic mice. Proc Natl Acad Sci U S A 1994, 91(21):9710-9714.

83. Rossiter H, van Reijsen F, Mudde GC, Kalthoff F, Bruijnzeel-Koomen CA, Picker LJ, Kupper TS: Skin disease-related T cells bind to endothelial selectins: expression of cutaneous lymphocyte antigen (CLA) predicts E-selectin but not P-selectin binding. Eur J Immunol 1994, 24(1):205-210.

84. Mizutani H, Roswit W, Hemperly J, Lawley T, Compton C, Swerlick R, Kupper TS: Human dermal microvascular endothelial cells express the 140-kD isoform of neural cell adhesion molecule. Biochem Biophys Res Commun 1994, 203(1):686-693.

85. Groves RW, Sherman L, Mizutani H, Dower SK, Kupper TS: Detection of interleukin-1 receptors in human epidermis. Induction of the type II receptor after organ culture and in psoriasis. Am J Pathol 1994, 145(5):1048-1056.

86. Alon R, Rossiter H, Wang X, Springer TA, Kupper TS: Distinct cell surface ligands mediate T lymphocyte attachment and rolling on P and E selectin under physiological flow. J Cell Biol 1994, 127(5):1485-1495.

87. Peterseim UM, Sarkar SN, Kupper TS: Production of IL-3 by non-transformed primary neonatal murine keratinocytes: evidence for constitutive IL-3 gene expression in neonatal epidermis. Cytokine 1993, 5(3):240-249.

88. Kupper TS, Ferguson TA: A potential pathophysiologic role for alpha 2 beta 1 integrin in human eye diseases involving vitreoretinal traction. FASEB J 1993, 7(14):1401-1406.

89. Ferguson TA, Kupper TS: Antigen-independent processes in antigen-specific immunity. A role for alpha 4 integrin. J Immunol 1993, 150(4):1172-1182.

90. Buchsbaum ME, Kupper TS, Murphy GF: Differential induction of intercellular adhesion molecule-1 in human skin by recombinant cytokines. J Cutan Pathol 1993, 20(1):21-27.

91. Chan BM, Kassner PD, Schiro JA, Byers HR, Kupper TS, Hemler ME: Distinct cellular functions mediated by different VLA integrin alpha subunit cytoplasmic domains. Cell 1992, 68(6):1051-1060.

92. Schiro JA, Kupper TS: Cutaneous eruptions during GM-CSF infusion. Clues for cytokine biology. Arch Dermatol 1991, 127(1):110-112.

93. Schiro JA, Chan BM, Roswit WT, Kassner PD, Pentland AP, Hemler ME, Eisen AZ, Kupper TS: Integrin alpha 2 beta 1 (VLA-2) mediates reorganization and contraction of collagen matrices by human cells. Cell 1991, 67(2):403-410.

94. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS: Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 1991, 174(4):821-825.

95. Mizutani H, Mizutani T, Okada H, Kupper TS, Shimizu M: Round fingerpad sign: an early sign of scleroderma. J Am Acad Dermatol 1991, 24(1):67-69.

96. Mizutani H, Black R, Kupper TS: Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. Different strategies of IL-1 production and processing in monocytes and keratinocytes. J Clin Invest 1991, 87(3):1066-1071.

97. Ferguson TA, Mizutani H, Kupper TS: Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo. Proc Natl Acad Sci U S A 1991, 88(18):8072-8076.

98. Baker CC, Niven-Fairchild T, Caragnano C, Kupper TS: Outcome following femur fracture and subsequent cecal ligation and puncture in endotoxin-sensitive (C3H/HeN) and endotoxin-resistant (C3H/HeJ) mice. J Surg Res 1991, 50(2):170-174.

99. Baker CC, Niven-Fairchild AT, Yamada A, Caragnano CL, Kupper TS: Macrophage antigen presentation and interleukin 1 production after cecal ligation and puncture in C3H/HeN and C3H/HeJ mice. Arch Surg 1991, 126(2):253-257; discussion 257-258.

100. Kupper TS: Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations. J Clin Invest 1990, 86(6):1783-1789.

101. Kupper TS: The activated keratinocyte: a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses. J Invest Dermatol 1990, 94(6 Suppl):146S-150S.

102. Galy AH, Dinarello CA, Kupper TS, Kameda A, Hadden JW: Effects of cytokines on human thymic epithelial cells in culture. II. Recombinant IL 1 stimulates thymic epithelial cells to produce IL6 and GM-CSF. Cell Immunol 1990, 129(1):161-175.

103. Dower SK, Qwarnstrom EE, Page RC, Blanton RA, Kupper TS, Raines E, Ross R, Sims JE: Biology of the interleukin-1 receptor. J Invest Dermatol 1990, 94(6 Suppl):68S-73S.

104. Schneider EG, Armant DR, Kupper TS, Polan ML: Absence of a direct effect of recombinant interleukins and cultured peritoneal macrophages on early embryonic development in the mouse. Biol Reprod 1989, 40(4):825-833.

105. Mizutani H, May LT, Sehgal PB, Kupper TS: Synergistic interactions of IL-1 and IL-6 in T cell activation. Mitogen but not antigen receptor-induced proliferation of a cloned T helper cell line is enhanced by exogenous IL-6. J Immunol 1989, 143(3):896-901.

106. Kupper TS, Min K, Sehgal P, Mizutani H, Birchall N, Ray A, May L: Production of IL-6 by keratinocytes. Implications for epidermal inflammation and immunity. Ann N Y Acad Sci 1989, 557:454-464; discussion 464-455.

107. Kupper TS: Mechanisms of cutaneous inflammation. Interactions between epidermal cytokines, adhesion molecules, and leukocytes. Arch Dermatol 1989, 125(10):1406-1412.

108. Kupper TS: Production of cytokines by epithelial tissues. A new model for cutaneous inflammation. Am J Dermatopathol 1989, 11(1):69-73.

109. Horowitz MC, Coleman DL, Flood PM, Kupper TS, Jilka RL: Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989, 83(1):149-157.

110. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 1989, 86(16):6367-6371.

111. Blanton RA, Kupper TS, McDougall JK, Dower S: Regulation of interleukin 1 and its receptor in human keratinocytes. Proc Natl Acad Sci U S A 1989, 86(4):1273-1277.

112. Kupper TS, Lee F, Coleman D, Chodakewitz J, Flood P, Horowitz M: Keratinocyte derived T-cell growth factor (KTGF) is identical to granulocyte macrophage colony stimulating factor (GM-CSF). J Invest Dermatol 1988, 91(2):185-188.

113. Kupper TS, Lee F, Birchall N, Clark S, Dower S: Interleukin 1 binds to specific receptors on human keratinocytes and induces granulocyte macrophage colony-stimulating factor mRNA and protein. A potential autocrine role for interleukin 1 in epidermis. J Clin Invest 1988, 82(5):1787-1792.

114. Kupper TS, Horowitz M, Birchall N, Mizutani H, Coleman D, McGuire J, Flood P, Dower S, Lee F: Hematopoietic, lymphopoietic, and proinflammatory cytokines produced by human and murine keratinocytes. Ann N Y Acad Sci 1988, 548:262-270.

115. Kupper TS: Interleukin 1 and other human keratinocyte cytokines: molecular and functional characterization. Adv Dermatol 1988, 3:293-307.

116. Jacobson BK, Cuono CB, Kupper TS, Baker CC: Immunologic alterations following excisional wounding and immediate repair with syngeneic or allogeneic skin grafts. J Burn Care Rehabil 1988, 9(4):354-358.

117. Chodakewitz JA, Kupper TS, Coleman DL: Keratinocyte-derived granulocyte/macrophage colony-stimulating factor induces DNA synthesis by peritoneal macrophages. J Immunol 1988, 140(3):832-836.

118. Breslin RJ, Barbul A, Kupper TS, Knud-Hansen JP, Wasserkrug HL, Efron G: Generation of an anti-interleukin 2 factor in healing wounds. Arch Surg 1988, 123(3):305-308.

119. Stephan RN, Kupper TS, Geha AS, Baue AE, Chaudry IH: Hemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis. Arch Surg 1987, 122(1):62-68.

120. Kupper TS, Edelson RL: The role of cytokines in the pathophysiology of T cell mediated skin disease. J Dermatol 1987, 14(6):517-523.

121. Kupper TS, Chua AO, Flood P, McGuire J, Gubler U: Interleukin 1 gene expression in cultured human keratinocytes is augmented by ultraviolet irradiation. J Clin Invest 1987, 80(2):430-436.

122. Goldminz D, Kupper TS, McGuire J: Keratinocyte membrane-associated epidermal cell-derived thymocyte-activating factor (ETAF). J Invest Dermatol 1987, 88(1):97-100.

123. Coleman DL, Kupper TS, Flood PM, Fultz CC, Horowitz MC: Characterization of a keratinocyte-derived T cell growth factor distinct from interleukin 2 and B cell stimulatory factor 1. J Immunol 1987, 138(10):3314-3318.

124. Baker CC, Yamada AH, Faist E, Kupper TS: Interleukin-1 and T cell function following injury. J Burn Care Rehabil 1987, 8(6):503-508.

125. Kupper TS, McGuire J: Hydrocortisone reduces both constitutive and UV-elicited release of epidermal thymocyte activating factor (ETAF) by cultured keratinocytes. J Invest Dermatol 1986, 87(5):570-573.

126. Kupper TS, Deitch EA, Baker CC, Wong WC: The human burn wound as a primary source of interleukin-1 activity. Surgery 1986, 100(2):409-415.

127. Kupper TS, Coleman DL, McGuire J, Goldminz D, Horowitz MC: Keratinocyte-derived T-cell growth factor: a T-cell growth factor functionally distinct from interleukin 2. Proc Natl Acad Sci U S A 1986, 83(12):4451-4455.

128. Kupper TS, Ballard DW, Chua AO, McGuire JS, Flood PM, Horowitz MC, Langdon R, Lightfoot L, Gubler U: Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1. J Exp Med 1986, 164(6):2095-2100.

129. Faist E, Kupper TS, Baker CC, Chaudry IH, Dwyer J, Baue AE: Depression of cellular immunity after major injury. Its association with posttraumatic complications and its reversal with immunomodulation. Arch Surg 1986, 121(9):1000-1005.

130. Kupper TS, Green DR, Durum SK, Baker CC: Defective antigen presentation to a cloned T helper cell by macrophages from burned mice can be restored with interleukin-1. Surgery 1985, 98(2):199-206.

131. Kupper TS, Baker CC, Ferguson TA, Green DR: A burn induced Ly-2 suppressor T cell lowers resistance to bacterial infection. J Surg Res 1985, 38(6):606-612.

132. Kupper TS, Green DR, Chaudry IH, Fox A, Baue AE: A cyclophosphamide-sensitive suppressor T cell circuit induced by thermal injury. Surgery 1984, 95(6):699-706.

133. Kupper TS, Green DR: Immunoregulation after thermal injury: sequential appearance of I-J+, Ly-1 T suppressor inducer cells and Ly-2 T suppressor effector cells following thermal trauma in mice. J Immunol 1984, 133(6):3047-3053.

134. Fusi S, Kupper TS, Green DR, Ariyan S: Reversal of postburn immunosuppression by the administration of vitamin A. Surgery 1984, 96(2):330-335.

135. Chaudry IH, Kupper TS, Schleck S, Clemens MG, Baue AE: Impairment of reticuloendothelial function following thermal injury and its restoration with ATP-MgCl2 administration. Circ Shock 1982, 9(3):297-305.

Abrar Qureshi, M.D., M.P.H.

1. Qureshi AA, Choi HK, Setty AR, Curhan GC: Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009, 145(4):379-382.

2. Pomerantz RG, Mody E, Husni ME, Qureshi AA: Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy. J Drugs Dermatol 2009, 8(4):406-412.

3. Nan H, Kraft P, Qureshi AA, Guo Q, Chen C, Hankinson SE, Hu FB, Thomas G, Hoover RN, Chanock S et al: Genome-Wide Association Study of Tanning Phenotype in a Population of European Ancestry. J Invest Dermatol 2009.

4. Hu SW, Bevona C, Winterfield L, Qureshi AA, Li VW: Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with infliximab: report of a case. Arch Dermatol 2009, 145(4):437-439.

5. Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ, De Vivo I: A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009, 129(2):415-421.

6. Gu F, Qureshi AA, Kraft P, Guo Q, Hunter DJ, Han J: Polymorphisms in genes involved in DNA repair, cell growth, oxidative stress and inflammatory response, and melanoma risk. Br J Dermatol 2009, 161(1):209-212.

7. Dominguez PL, Husni ME, Holt EW, Tyler S, Qureshi AA: Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 2009.

8. Dominguez PL, Assarpour A, Kuo H, Holt EW, Tyler S, Qureshi AA: Development and pilot-testing of a psoriasis screening tool. Br J Dermatol 2009.

9. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB et al: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2008.

10. Qureshi AA, Laden F, Colditz GA, Hunter DJ: Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med 2008, 168(5):501-507.

11. Qureshi AA, Dominguez P, Duffin KC, Gladman DD, Helliwell P, Mease PJ, Husni ME: Psoriatic arthritis screening tools. J Rheumatol 2008, 35(7):1423-1425.

12. Nan H, Qureshi AA, Hunter DJ, Han J: Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. Br J Dermatol 2008, 159(2):314-321.

13. Hu SW, Holt EW, Husni ME, Qureshi AA: Willingness-to-Pay Stated Preferences for 8 Health-Related Quality-of-Life Domains in Psoriatic Arthritis: A Pilot Study. Semin Arthritis Rheum 2008.

14. Hu S, Cohen D, Murphy G, Mody E, Qureshi AA: Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis 2008, 81(4):336-338.

15. Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A, Hankinson SE, Hu FB, Duffy DL, Zhao ZZ et al: A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008, 4(5):e1000074.

16. Gu F, Qureshi AA, Niu T, Kraft P, Guo Q, Hunter DJ, Han J: Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res 2008, 18(5):330-335.

17. Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I et al: Clinical and genetic registries in psoriatic disease. J Rheumatol 2008, 35(7):1458-1463.

18. Delfino M, Jr., Holt EW, Taylor CR, Wittenberg E, Qureshi AA: Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008, 59(3):439-447.

19. Pomerantz RG, Husni ME, Mody E, Qureshi AA: Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol 2007, 157(6):1274-1275.

20. Qureshi AA, Brandling-Bennett HA, Wittenberg E, Chen SC, Sober AJ, Kvedar JC: Willingness-to-pay stated preferences for telemedicine versus in-person visits in patients with a history of psoriasis or melanoma. Telemed J E Health 2006, 12(6):639-643.

21. Qureshi AA, Brandling-Bennett HA, Wittenberg E, Chen SC, Sober AJ, Kvedar JC: Willingness-to-pay stated preferences for telemedicine versus in-person visits in patients with a history of psoriasis or melanoma. Telemed J E Health 2006, 12(6):639-643.

22. Qureshi AA, Brandling-Bennett HA, Giberti S, McClure D, Halpern EF, Kvedar JC: Evaluation of digital skin images submitted by patients who received practical training or an online tutorial. J Telemed Telecare 2006, 12(2):79-82.

23. Qureshi AA, Brandling-Bennett HA, Giberti S, McClure D, Halpern EF, Kvedar JC: Evaluation of digital skin images submitted by patients who received practical training or an online tutorial. J Telemed Telecare 2006, 12(2):79-82.

24. Firoz BF, Lee SJ, Nghiem P, Qureshi AA: Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol 2006, 142(2):175-182.

25. Firoz BF, Lee SJ, Nghiem P, Qureshi AA: Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol 2006, 142(2):175-182.

26. Iuga AO, Qureshi AA, Lerner EA: Nitric oxide is toxic to melanocytes in vitro. Pigment Cell Res 2004, 17(3):302-306.

27. Qureshi AA, Kvedar JC: Patient knowledge and attitude toward information technology and teledermatology: some tentative findings. Telemed J E Health 2003, 9(3):259-264.

28. Lerner LH, Qureshi AA, Reddy BV, Lerner EA: Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 2000, 114(1):196-199.

29. Qureshi AA, Lerner LH, Lerner EA: From bedside to the bench and back. Nitric oxide and the cutis. Arch Dermatol 1996, 132(8):889-893.

30. Qureshi AA, Lehmann JW, Peterson DM: Amaranth and its oil inhibit cholesterol biosynthesis in 6-week-old female chickens. J Nutr 1996, 126(8):1972-1978.

31. Qureshi AA, Hosoi J, Xu S, Takashima A, Granstein RD, Lerner EA: Langerhans cells express inducible nitric oxide synthase and produce nitric oxide. J Invest Dermatol 1996, 107(6):815-821.

32. Qureshi AA, Asahina A, Ohnuma M, Tajima M, Granstein RD, Lerner EA: Immunomodulatory properties of maxadilan, the vasodilator peptide from sand fly salivary gland extracts. Am J Trop Med Hyg 1996, 54(6):665-671.

33. Ahmad HR, Akhtar S, Khan MA, Khan KS, Qureshi AA, Romana H, Hughes PF: Dynamic and steady state response of heart rate to orthostatic stress in normotensive and hypertensive pregnant women. Eur J Obstet Gynecol Reprod Biol 1996, 66(1):31-37.

34. Abbas Z, Qureshi AA, Sheikh H, Jafri SM, Khan AH: Peculiar histopathological features of giardiasis in distal duodenal biopsies. J Pak Med Assoc 1994, 44(9):206-209.

James Rheinwald, Ph.D.

1. Dabelsteen S, Hercule P, Barron P, Rice M, Dorsainville G, Rheinwald JG: Epithelial Cells Derived from Human Embryonic Stem Cells Display P16(INK4A) Senescence, Hypermotility, and Differentiation Properties Shared by Many P63(+) Somatic Cell Types. Stem Cells 2009, 27(6):1388-1399.

2. Natarajan E, Omobono JD, 2nd, Guo Z, Hopkinson S, Lazar AJ, Brenn T, Jones JC, Rheinwald JG: A keratinocyte hypermotility/growth-arrest response involving laminin 5 and p16INK4A activated in wound healing and senescence. Am J Pathol 2006, 168(6):1821-1837.

3. Iuchi S, Dabelsteen S, Easley K, Rheinwald JG, Green H: Immortalized keratinocyte lines derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2006, 103(6):1792-1797.

4. Natarajan E, Omobono JD, 2nd, Jones JC, Rheinwald JG: Co-expression of p16INK4A and laminin 5 by keratinocytes: a wound-healing response coupling hypermotility with growth arrest that goes awry during epithelial neoplastic progression. J Investig Dermatol Symp Proc 2005, 10(2):72-85.

5. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ et al: Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005, 166(6):1827-1840.

6. Kim M, Yang H, Kim SK, Reche PA, Tirabassi RS, Hussey RE, Chishti Y, Rheinwald JG, Morehead TJ, Zech T et al: Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J Biol Chem 2004, 279(24):25838-25848.

7. Rheinwald JG: Becoming a scientist: what I learned from Gunny. Biochem Biophys Res Commun 2003, 312(1):61-64.

8. Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG: Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol 2003, 163(2):477-491.

9. Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, Munger K, Daly CM, Rosl F, Rollins BJ: Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 2003, 107(3):407-415.

10. Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catricala C, O'Toole KM: A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002, 22(14):5157-5172.

11. Verselis SJ, Rheinwald JG, Fraumeni JF, Jr., Li FP: Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 2000, 19(37):4230-4235.

12. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG: Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000, 20(4):1436-1447.

13. Schon M, Benwood J, O'Connell-Willstaedt T, Rheinwald JG: Human sweat gland myoepithelial cells express a unique set of cytokeratins and reveal the potential for alternative epithelial and mesenchymal differentiation states in culture. J Cell Sci 1999, 112 ( Pt 12):1925-1936.

14. Murphy JE, Rheinwald JG: Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy. Hum Gene Ther 1997, 8(16):1867-1879.

15. Fichorova RN, Rheinwald JG, Anderson DJ: Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 1997, 57(4):847-855.

16. Schrager HM, Rheinwald JG, Wessels MR: Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest 1996, 98(9):1954-1958.

17. Schon M, Rheinwald JG: A limited role for retinoic acid and retinoic acid receptors RAR alpha and RAR beta in regulating keratin 19 expression and keratinization in oral and epidermal keratinocytes. J Invest Dermatol 1996, 107(3):428-438.

18. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G et al: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993, 4(4):415-420.

19. Lindberg K, Brown ME, Chaves HV, Kenyon KR, Rheinwald JG: In vitro propagation of human ocular surface epithelial cells for transplantation. Invest Ophthalmol Vis Sci 1993, 34(9):2672-2679.

20. Hu L, Crowe DL, Rheinwald JG, Chambon P, Gudas LJ: Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res 1991, 51(15):3972-3981.

21. Crowe DL, Hu L, Gudas LJ, Rheinwald JG: Variable expression of retinoic acid receptor (RAR beta) mRNA in human oral and epidermal keratinocytes; relation to keratin 19 expression and keratinization potential. Differentiation 1991, 48(3):199-208.

22. Lindberg K, Rheinwald JG: Three distinct keratinocyte subtypes identified in human oral epithelium by their patterns of keratin expression in culture and in xenografts. Differentiation 1990, 45(3):230-241.

23. Henrard DR, Thornley AT, Brown ML, Rheinwald JG: Specific effects of ras oncogene expression on the growth and histogenesis of human epidermal keratinocytes. Oncogene 1990, 5(4):475-481.

24. Demetri GD, Ernst TJ, Pratt ES, 2nd, Zenzie BW, Rheinwald JG, Griffin JD: Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest 1990, 86(4):1261-1269.

25. Rollins BJ, O'Connell TM, Bennett G, Burton LE, Stiles CD, Rheinwald JG: Environment-dependent growth inhibition of human epidermal keratinocytes by recombinant human transforming growth factor-beta. J Cell Physiol 1989, 139(3):455-462.

26. Rheinwald JG: Human epidermal keratinocyte cell culture and xenograft systems: applications in the detection of potential chemical carcinogens and the study of epidermal transformation. Prog Clin Biol Res 1989, 298:113-125.

27. Lindberg K, Rheinwald JG: Suprabasal 40 kd keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium. Am J Pathol 1989, 134(1):89-98.

28. Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD: Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 1989, 74(3):940-946.

29. Cicila GT, O'Connell TM, Hahn WC, Rheinwald JG: Cloned cDNA sequence for the human mesothelial protein 'mesosecrin' discloses its identity as a plasminogen activator inhibitor (PAI-1) and a recent evolutionary change in transcript processing. J Cell Sci 1989, 94 ( Pt 1):1-10.

30. Tubo RA, Rheinwald JG: Normal human mesothelial cells and fibroblasts transfected with the EJras oncogene become EGF-independent, but are not malignantly transformed. Oncogene Res 1987, 1(4):407-421.

31. Rheinwald JG, Jorgensen JL, Hahn WC, Terpstra AJ, O'Connell TM, Plummer KK: Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol 1987, 104(2):263-275.

32. Rheinwald JG, O'Connell TM: Intermediate filament proteins as distinguishing markers of cell type and differentiated state in cultured human urinary tract epithelia. Ann N Y Acad Sci 1985, 455:259-267.

33. La Rocca PJ, Rheinwald JG: Anchorage-independent growth of normal human mesothelial cells: a sensitive bioassay for EGF which discloses the absence of this factor in fetal calf serum. In Vitro Cell Dev Biol 1985, 21(1):67-72.

34. Weichselbaum R, Dahlberg W, Little JB, Ervin TJ, Miller D, Hellman S, Rheinwald JG: Cellular X-ray repair parameters of early passage squamous cell carcinoma lines derived from patients with known responses to radiotherapy. Br J Cancer 1984, 49(5):595-601.

35. Nadakavukaren KK, Summerhayes IC, Salcedo BF, Rheinwald JG, Chen LB: A monoclonal antibody recognizing a keratin filament protein in a subset of transitional and glandular epithelia. Differentiation 1984, 27(3):209-220.

36. LaRocca PJ, Rheinwald JG: Coexpression of simple epithelial keratins and vimentin by human mesothelium and mesothelioma in vivo and in culture. Cancer Res 1984, 44(7):2991-2999.

37. Allen-Hoffmann BL, Rheinwald JG: Polycyclic aromatic hydrocarbon mutagenesis of human epidermal keratinocytes in culture. Proc Natl Acad Sci U S A 1984, 81(24):7802-7806.

38. Kim KH, Rheinwald JG, Fuchs EV: Tissue specificity of epithelial keratins: differential expression of mRNAs from two multigene families. Mol Cell Biol 1983, 3(4):495-502.

39. Connell ND, Rheinwald JG: Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell 1983, 34(1):245-253.

40. Wu YJ, Parker LM, Binder NE, Beckett MA, Sinard JH, Griffiths CT, Rheinwald JG: The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell 1982, 31(3 Pt 2):693-703.

41. Rheinwald JG: Human squamous cell carcinoma in culture: a defect in terminal differentiation and its relation to malignancy. Natl Cancer Inst Monogr 1982, 60:133-138.

42. Wu YJ, Rheinwald JG: A new small (40 kd) keratin filament protein made by some cultured human squamous cell carcinomas. Cell 1981, 25(3):627-635.

43. Rheinwald JG, Beckett MA: Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 1981, 41(5):1657-1663.

44. Didinsky JB, Rheinwald JG: Failure of hydrocortisone or growth factors to influence the senescence of fibroblasts in a new culture system for assessing replicative lifespan. J Cell Physiol 1981, 109(1):171-179.

45. Rheinwald JG, Beckett MA: Defective terminal differentiation in culture as a consistent and selectable character of malignant human keratinocytes. Cell 1980, 22(2 Pt 2):629-632.

46. Rheinwald JG: Serial cultivation of normal human epidermal keratinocytes. Methods Cell Biol 1980, 21A:229-254.

47. Rheinwald JG: The role of terminal differentiation in the finite culture lifetime of the human epidermal keratinocyte. Int Rev Cytol Suppl 1979(10):25-33.

48. Rheinwald JG, Green H: Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature 1977, 265(5593):421-424.

49. Green H, Rheinwald JG, Sun TT: Properties of an epithelial cell type in culture: the epidermal keratinocyte and its dependence on products of the fibroblast. Prog Clin Biol Res 1977, 17:493-500.

50. Rheinwald JG, Green H: Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma. Cell 1975, 6(3):317-330.

51. Rheinwald JG, Green H: Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975, 6(3):331-343.

52. Rheinwald JG, Green H: Growth of cultured mammalian cells on secondary glucose sources. Cell 1974, 2(4):287-293.

53. Rheinwald JG, Chakrabarty AM, Gunsalus IC: A transmissible plasmid controlling camphor oxidation in Pseudomonas putida. Proc Natl Acad Sci U S A 1973, 70(3):885-889.

Robert Sackstein, M.D., Ph.D.

1. Sackstein R, Fuhlbrigge R: Western Blot Analysis of Adhesive Interactions under Fluid Shear Conditions: The Blot Rolling Assay. Methods Mol Biol 2009, 536:343-354.

2. Nigro J, Wang A, Mukhopadhyay D, Lauer ME, Midura RJ, Sackstein R, Hascall VC: Regulation of heparan sulfate and chondroitin sulfate glycosaminoglycan biosynthesis by 4-fluoro-glucosamine in murine airway smooth muscle cells. J Biol Chem 2009.

3. Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA: Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol 2008, 36(4):464-472.

4. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R: Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008, 14(2):181-187.

5. Resto VA, Burdick MM, Dagia NM, McCammon SD, Fennewald SM, Sackstein R: L-selectin-mediated lymphocyte-cancer cell interactions under low fluid shear conditions. J Biol Chem 2008, 283(23):15816-15824.

6. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A et al: SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008, 112(1):150-158.

7. Gadhoum SZ, Sackstein R: CD15 expression in human myeloid cell differentiation is regulated by sialidase activity. Nat Chem Biol 2008, 4(12):751-757.

8. Schreiber TH, Shinder V, Cain DW, Alon R, Sackstein R: Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. Blood 2007, 109(4):1381-1386.

9. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD: Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007, 104(13):5431-5436.

10. Sackstein R, Fuhlbrigge R: The blot rolling assay: a method for identifying adhesion molecules mediating binding under shear conditions. Methods Mol Biol 2006, 341:217-226.

11. Sackstein R: A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 2006, 12(1 Suppl 1):2-8.

12. Hanley WD, Napier SL, Burdick MM, Schnaar RL, Sackstein R, Konstantopoulos K: Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J 2006, 20(2):337-339.

13. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS: CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006, 107(4):1421-1426.

14. Dagia NM, Gadhoum SZ, Knoblauch CA, Spencer JA, Zamiri P, Lin CP, Sackstein R: G-CSF induces E-selectin ligand expression on human myeloid cells. Nat Med 2006, 12(10):1185-1190.

15. Burdick MM, Chu JT, Godar S, Sackstein R: HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem 2006, 281(20):13899-13905.

16. Sackstein R: The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol 2005, 12(6):444-450.

17. Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R: CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res 2005, 65(13):5812-5817.

18. Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S, Preffer F, Shaffer J, Tarbell N, Sackstein R et al: Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005, 128(3):351-359.

19. Sackstein R: The bone marrow is akin to skin: HCELL and the biology of hematopoietic stem cell homing. J Investig Dermatol Symp Proc 2004, 9(3):215-223.

20. Sackstein R: The bone marrow is akin to skin: HCELL and the biology of hematopoietic stem cell homing. J Invest Dermatol 2004, 122(5):1061-1069.

21. Milinkovic M, Antin JH, Hergrueter CA, Underhill CB, Sackstein R: CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. Blood 2004, 103(2):740-742.

22. Elfenbein GJ, Sackstein R, Oblon DJ: Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No! Blood Cells Mol Dis 2004, 32(1):106-111.

23. Elfenbein GJ, Sackstein R: Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004, 32(4):327-339.

24. Sackstein R, Messina JL, Elfenbein GJ: In vitro adherence of lymphocytes to dermal endothelium under shear stress: implications in pathobiology and steroid therapy of acute cutaneous GVHD. Blood 2003, 101(2):771-778.

25. Kraus AB, Shaffer J, Toh HC, Preffer F, Dombkowski D, Saidman S, Colby C, George R, McAfee S, Sackstein R et al: Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 2003, 31(7):609-621.

26. Dimitroff CJ, Kupper TS, Sackstein R: Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003, 112(7):1008-1018.

27. Dimitroff CJ, Bernacki RJ, Sackstein R: Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 2003, 101(2):602-610.

28. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR: Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003, 9(5):320-329.

29. Daly A, McAfee S, Dey B, Colby C, Schulte L, Yeap B, Sackstein R, Tarbell NJ, Sachs D, Sykes M et al: Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003, 9(6):373-382.

30. Toh HC, Spitzer TR, Preffer F, Alexander SI, McAfee S, Dombkowski D, Clark JS, Colby C, Saidman S, Sackstein R et al: Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant. Cytokines Cell Mol Ther 2002, 7(2):43-47.

31. Theodore PR, Simon AR, Warrens AN, Sackstein R, Sykes M: Porcine mononuclear cells adhere to human fibronectin independently of very late antigen-5: implications for donor-specific tolerance induction in xenotransplantation. Xenotransplantation 2002, 9(4):277-289.

32. Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R: Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. J Immunol 2002, 168(11):5645-5651.

33. Buhler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, Saidman SL, Sackstein R, McAfee S, Dey B et al: Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002, 74(10):1405-1409.

34. Buhler L, Kurilla-Mahon B, Chang Q, Abraham S, Alwayn IP, Appel JZ, 3rd, Newman D, Awwad M, White-Scharf ME, Sackstein R et al: Cryopreservation and mycophenolate therapy are detrimental to hematopoietic progenitor cells. Transplantation 2002, 74(8):1159-1166.

35. Buhler L, Awwad M, Treter S, Chang Q, Basker M, Alwayn IP, Teranishi K, Ericsson T, Moran K, Harper D et al: Pig hematopoietic cell chimerism in baboons conditioned with a nonmyeloablative regimen and CD154 blockade. Transplantation 2002, 73(1):12-22.

36. Gonzalez S, Sackstein R, Anderson RR, Rajadhyaksha M: Real-time evidence of in vivo leukocyte trafficking in human skin by reflectance confocal microscopy. J Invest Dermatol 2001, 117(2):384-386.

37. Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SP: A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol 2001, 167(10):5531-5534.

38. Dimitroff CJ, Lee JY, Schor KS, Sandmaier BM, Sackstein R: differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1. J Biol Chem 2001, 276(50):47623-47631.

39. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R: CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001, 153(6):1277-1286.

40. Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M et al: Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001, 7(11):604-612.

41. Buhler L, Goepfert C, Kitamura H, Basker M, Gojo S, Alwayn IP, Chang Q, Down JD, Tsai H, Wise R et al: Porcine hematopoietic cell xenotransplantation in nonhuman primates is complicated by thrombotic microangiopathy. Bone Marrow Transplant 2001, 27(12):1227-1236.

42. Alwayn IP, Buhler L, Appel JZ, 3rd, Goepfert C, Csizmadia E, Correa L, Harper D, Kitamura H, Down J, Awwad M et al: Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. Transplantation 2001, 71(11):1601-1609.

43. Toh HC, McAfee SL, Sackstein R, Multani P, Cox BF, Garcia-Carbonero R, Colby C, Spitzer TR: High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Bone Marrow Transplant 2000, 25(1):19-24.

44. Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C et al: Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000, 6(3A):309-320.

45. Sackstein R, Dimitroff CJ: A hematopoietic cell L-selectin ligand that is distinct from PSGL-1 and displays N-glycan-dependent binding activity. Blood 2000, 96(8):2765-2774.

46. Gopfert C, Buhler L, Wise R, Basker M, Gojo S, Imai M, Alwayn I, Sachs DH, Sackstein R, Cooper DK et al: Von willebrand factor concentration, multimeric patterns, and cleaving protease activity in baboons undergoing xenogeneic peripheral blood stem cell transplantation. Transplant Proc 2000, 32(5):990.

47. Dimitroff CJ, Lee JY, Fuhlbrigge RC, Sackstein R: A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci U S A 2000, 97(25):13841-13846.

48. Colby C, Chang Q, Fuchimoto Y, Ferrara V, Murphy M, Sackstein R, Spitzer TR, White-Scharf ME, Sachs DH: Cytokine-mobilized peripheral blood progenitor cells for allogeneic reconstitution of miniature swine. Transplantation 2000, 69(1):135-140.

49. Buhler L, Basker M, Alwayn IP, Goepfert C, Kitamura H, Kawai T, Gojo S, Kozlowski T, Ierino FL, Awwad M et al: Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000, 70(9):1323-1331.

50. Buhler L, Awwad M, Basker M, Gojo S, Watts A, Treter S, Nash K, Oravec G, Chang Q, Thall A et al: High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000, 69(11):2296-2304.

51. Buhler L, Awwad M, Basker M, Gojo S, Thall A, Down JD, Sykes M, Andrews D, Sackstein R, White-Scharf ME et al: A nonmyeloablative regimen with CD40L blockade leads to humoral and cellular hyporesponsiveness to pig hematopoietic cells in baboons. Transplant Proc 2000, 32(5):1100.

52. Alwayn IP, Buhler L, Basker M, Goepfert C, Kawai T, Kozlowski T, Ierino F, Sachs DH, Sackstein R, Robson SC et al: Coagulation/thrombotic disorders associated with organ and cell xenotransplantation. Transplant Proc 2000, 32(5):1099.

53. Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR: Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999, 24(8):891-895.

54. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR: Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999, 353(9166):1755-1759.

55. Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sackstein R, Saidman S, Colby C, Sykes M, Sachs DH, Cosimi AB: Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999, 68(4):480-484.

56. Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R et al: The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999, 94(12):4233-4246.

57. Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T: A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 24(8):897-902.

58. Sackstein R, Fu L, Allen KL: A hematopoietic cell L-selectin ligand exhibits sulfate-independent binding activity. Blood 1997, 89(8):2773-2781.

59. Sackstein R: Expression of an L-selectin ligand on hematopoietic progenitor cells. Acta Haematol 1997, 97(1-2):22-28.

60. Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R et al: High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997, 20(8):653-656.

61. Wasik MA, Sackstein R, Novick D, Butmarc JR, Zhang Q, Vonderheid EC, Kadin ME: Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2. Hum Pathol 1996, 27(7):738-744.

62. Sackstein R, Meng L, Xu XM, Chin YH: Evidence of post-transcriptional regulation of L-selectin gene expression in rat lymphoid cells. Immunology 1995, 85(2):198-204.

63. Sackstein R, Borenstein M: The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. J Investig Med 1995, 43(1):68-77.

64. Sackstein R: Lymphocyte migration following bone marrow transplantation. Ann N Y Acad Sci 1995, 770:177-188.

65. Sackstein R: Physiologic basis of steroid-induced immunosuppression. Effects on lymphocyte migration to lymph nodes. J Fla Med Assoc 1995, 82(9):613-615.

66. Sackstein R: Adoptive Immunotherapy: The Magic Bullet of Cancer Therapy? Cancer Control 1994, 1(1):65-66.

67. Oxley SM, Sackstein R: Detection of an L-selectin ligand on a hematopoietic progenitor cell line. Blood 1994, 84(10):3299-3306.

68. Sackstein R: Effects of methylprednisolone administration on lymphocyte LECAM-1, CD44, and LFA-1 expression. Implications for steroid-induced lymphopenia. Ann N Y Acad Sci 1993, 696:417-419.

69. Sackstein R: Physiologic migration of lymphocytes to lymph nodes following bone marrow transplantation: role in immune recovery. Semin Oncol 1993, 20(5 Suppl 6):34-39.

70. Gross JN, Sackstein RD, Song SL, Chang CJ, Kawinishi DT, Furman S: The antitachycardia pacing ICD: impact on patient selection and outcome. Pacing Clin Electrophysiol 1993, 16(1 Pt 2):165-169.

71. Gross JN, Sackstein RD, Furman S: Cardiac pacing and atrial arrhythmias. Cardiol Clin 1992, 10(4):609-617.

72. Chin YH, Sackstein R, Cai JP: Lymphocyte-homing receptors and preferential migration pathways. Proc Soc Exp Biol Med 1991, 196(4):374-380.

73. Chin YH, Falanga V, Streilein JW, Sackstein R: Lymphocyte recognition of psoriatic endothelium: evidence for a tissue-specific receptor/ligand interaction. J Invest Dermatol 1989, 93(2 Suppl):82S-87S.

74. Sackstein R, Falanga V, Streilein JW, Chin YH: Lymphocyte adhesion to psoriatic dermal endothelium is mediated by a tissue-specific receptor/ligand interaction. J Invest Dermatol 1988, 91(5):423-428.

75. Chin YH, Falanga V, Streilein JW, Sackstein R: Specific lymphocyte-endothelial cell interactions regulate migration into lymph nodes, Peyer's patches, and skin. Reg Immunol 1988, 1(1):78-83.

76. Whitehead AS, Sackstein R: Molecular biology of the human and mouse MHC class III genes: phylogenetic conservation, genetics and regulation of expression. Immunol Rev 1985, 87:185-208.

77. Sackstein R, Roos MH, Demant P, Colten HR: Subdivision of the S region of the mouse major histocompatibility complex by identification of genomic polymorphisms of the class III genes. Immunogenetics 1984, 20(3):321-330.

78. Sackstein R, Colten HR: Molecular regulation of MHC class III (C4 and factor B) gene expression in mouse peritoneal macrophages. J Immunol 1984, 133(3):1618-1626.

79. Chaplin DD, Sackstein R, Perlmutter DH, Weis JH, Kruse TA, Coligan J, Colten HR, Seidman JG: Expression of hemolytically active murine fourth component of complement in transfected L cells. Cell 1984, 37(2):569-576.

80. Sackstein R, Colten HR, Woods DE: Phylogenetic conservation of a class III major histocompatibility complex antigen, factor B. Isolation and nucleotide sequencing of mouse factor B cDNA clones. J Biol Chem 1983, 258(23):14693-14697.

Chrysalyne Schmults, M.D.

1. Jambusaria-Pahlajani A, Schmults CD, Miller CJ, Shin D, Williams J, Kurd SK, Gelfand JM: Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery. Dermatol Surg 2009, 35(1):9-15; discussion 15-16.

2. Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD: Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009, 35(4):574-585.

3. Ross AS, Schmults CD: Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 2006, 32(11):1309-1321.

4. Schmults CD: Laser treatment of vascular lesions. Dermatol Clin 2005, 23(4):745-755.

5. Schmults CD: High-risk cutaneous squamous cell carcinoma: identification and management. Adv Dermatol 2005, 21:133-152.

6. Li W, Marshall C, Mei L, Dzubow L, Schmults C, Dans M, Seykora J: Srcasm modulates EGF and Src-kinase signaling in keratinocytes. J Biol Chem 2005, 280(7):6036-6046.

7. Goldberg DJ, Marmur ES, Schmults C, Hussain M, Phelps R: Histologic and ultrastructural analysis of ultraviolet B laser and light source treatment of leukoderma in striae distensae. Dermatol Surg 2005, 31(4):385-387.

8. Schmults CD, Phelps R, Goldberg DJ: Nonablative facial remodeling: erythema reduction and histologic evidence of new collagen formation using a 300-microsecond 1064-nm Nd:YAG laser. Arch Dermatol 2004, 140(11):1373-1376.

9. Marmur ES, Schmults CD, Goldberg DJ: A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2004, 30(2 Pt 2):264-271.

10. Schmults CA: Psoriasis confined to the nails. Dermatol Online J 2003, 9(4):7.

11. Schmults CA: Scleroderma. Dermatol Online J 2003, 9(4):11.

12. Schmults C, Sidhu G, Urbanek RW: Aquagenic syringeal acrokeratoderma. Dermatol Online J 2003, 9(4):27.

13. Goldberg DJ, Schmults CD: Antibiotic prophylaxis for the prevention of endocarditis in dermatologic surgery: sources of controversy and directions for future research. J Drugs Dermatol 2003, 2(2):127-130.

14. Schmults CA: Acquired reactive perforating collagenosis. Dermatol Online J 2002, 8(2):8.

15. Schmults CA: Leukemia cutis (chronic lymphocytic leukemia-low grade B cell). Dermatol Online J 2002, 8(2):14.

Linda Wang, M.D., J.D.

1. Yang Q, Hornick JL, Granter SR, Wang LC: Merkel Cell Carcinoma: Lack of KIT Positivity and Implications for the Use of Imatinib Mesylate. In: Appl Immunohistochem Mol Morphol. 2009/03/12 edn; 2009.

2. Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass LF, Grekin RC, Hallahan DE et al: Merkel cell carcinoma. J Natl Compr Canc Netw 2009, 7(3):322-332.

3. Martin JE, Hsu MY, Wang LC: An unusual clinical presentation of multiple tumors of the follicular infundibulum. J Am Acad Dermatol 2009, 60(5):885-886.

4. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, Nghiem P: Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008, 58(3):375-381.

5. Gupta SG, Wang LC, Penas PF, Gellenthin M, Lee SJ, Nghiem P: Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 2006, 142(6):685-690.

6. Wang LC, Krunic AL, Medenica MM, Soltani K, Busbey S: Treatment of hemorrhagic lymphatic malformation of the tongue with a pulsed-dye laser. J Am Acad Dermatol 2005, 52(6):1088-1090.

7. Wang LC, Busbey S: Images in clinical medicine. Acquired acrodermatitis enteropathica. N Engl J Med 2005, 352(11):1121.

8. Lacouture ME, Kolanko E, Wang LC, Shea CR, Soltani K: Human papillomavirus-associated dysplastic condyloma of the tongue treated with Mohs micrographic surgery. Dermatol Surg 2005, 31(4):477-479.

9. Wang LC, Medenica MM, Shea CR, Busbey S: Pagetoid dyskeratosis of the hand. J Am Acad Dermatol 2004, 50(3):483-484.

10. Krunic AL, Wang LC, Soltani K, Weitzul S, Taylor RS: Digital anesthesia with epinephrine: an old myth revisited. J Am Acad Dermatol 2004, 51(5):755-759.

11. Wang LC, Medenica MM, Shea CR, Busbey S: Infliximab-induced eczematid-like purpura of Doucas and Kapetenakis. J Am Acad Dermatol 2003, 49(1):157-158.

12. Wang LC, Blanchard A, Judge DE, Lorincz AA, Medenica MM, Busbey S: Successful treatment of recurrent extramammary Paget's disease of the vulva with topical imiquimod 5% cream. J Am Acad Dermatol 2003, 49(4):769-772.

Andrew Werchniak, M.D.

1. Tsai KY, Brenn T, Werchniak AE: Nodular presentation of secondary syphilis. J Am Acad Dermatol 2007, 57(2 Suppl):S57-58.

2. Spenny ML, Walford J, Werchniak AE, Beltrani V, Brennick JB, Storm CA, Perry AE, Chapman MS: Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007, 79(2):149-152.

3. Perez AL, Werchniak AE: Antemortem diagnosis of rabies via nuchal skin biopsy. Arch Dermatol 2007, 143(5):663.

4. Werchniak AE, Perry AE, Dinulos JG: Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy (EPPER) in a patient with breast cancer. J Am Acad Dermatol 2006, 54(4):728-729.

5. Wartman DG, Perry A, Werchniak AE: Multiple nodules and plaques on the face and trunk. Cutaneous Rosai-Dorfman disease (RDD). Arch Dermatol 2006, 142(11):1501-1506.

6. Werchniak AE, Storm CA, Plunkett RW, Beutner EH, Dinulos JG: Treatment of pyostomatitis vegetans with topical tacrolimus. J Am Acad Dermatol 2005, 52(4):722-723.

7. Werchniak AE, Chaffee S, Dinulos JG: Methotrexate-induced bullous acral erythema in a child. J Am Acad Dermatol 2005, 52(5 Suppl 1):S93-95.

8. Werchniak AE, Storm CA, Dinulos JG: Hyperpigmented patches on the tongue of a young girl. Pigmented fungiform papillae of the tongue. Arch Dermatol 2004, 140(10):1275-1280.

9. Werchniak AE, Schwarzenberger K: Poison ivy: an underreported cause of erythema multiforme. J Am Acad Dermatol 2004, 51(5 Suppl):S159-160.

10. Werchniak AE, Cheng SX, Dhar AD, Klaus SN: Sarcoidosis presenting as tattoo changes in a patient undergoing treatment with interferon-alpha and ribavirin. Clin Exp Dermatol 2004, 29(5):547-548.

11. Werchniak AE, Baughman RD: Primary cutaneous cryptococcosis in an elderly man. Clin Exp Dermatol 2004, 29(2):159-160.

12. Dhar AD, Werchniak AE, Li Y, Brennick JB, Goldsmith CS, Kline R, Damon I, Klaus SN: Tanapox infection in a college student. N Engl J Med 2004, 350(4):361-366.

13. Werchniak AE, Herfort OP, Farrell TJ, Connolly KS, Baughman RD: Milker's nodule in a healthy young woman. J Am Acad Dermatol 2003, 49(5):910-911.

Hans Widlund, Ph.D.

1. Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T et al: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009, 459(7250):1085-1090.

2. Yokoyama S, Feige E, Poling LL, Levy C, Widlund HR, Khaled M, Kung AL, Fisher DE: Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 2008, 21(4):457-463.

3. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS: Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008, 14(23):7726-7732.

4. Widlund HR, Fisher DE: Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis. Pigment Cell Res 2007, 20(5):339-340.

5. Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR et al: Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007, 128(5):853-864.

6. Sun T, Hafler BP, Kaing S, Kitada M, Ligon KL, Widlund HR, Yuk DI, Stiles CD, Rowitch DH: Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. Dev Biol 2006, 292(1):152-164.

7. Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL et al: Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006, 9(6):473-484.

8. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD et al: BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005, 15(3):249-254.

9. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436(7047):117-122.

10. Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE: Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 2004, 64(2):509-516.

11. Kenney AM, Widlund HR, Rowitch DH: Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 2004, 131(1):217-228.

12. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004, 6(6):565-576.

13. Widlund HR, Fisher DE: Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 2003, 22(20):3035-3041.

14. Huber WE, Price ER, Widlund HR, Du J, Davis IJ, Wegner M, Fisher DE: A tissue-restricted cAMP transcriptional response: SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. J Biol Chem 2003, 278(46):45224-45230.

15. Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE: MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003, 163(1):333-343.

16. Widlund HR, Horstmann MA, Price ER, Cui J, Lessnick SL, Wu M, He X, Fisher DE: Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 2002, 158(6):1079-1087.

17. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF et al: Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002, 109(6):707-718.

18. Baksh S, Widlund HR, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, DeCaprio JA, Modiano JF, Burakoff SJ: NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell 2002, 10(5):1071-1081.

19. Widlund HR, Vitolo JM, Thiriet C, Hayes JJ: DNA sequence-dependent contributions of core histone tails to nucleosome stability: differential effects of acetylation and proteolytic tail removal. Biochemistry 2000, 39(13):3835-3841.

20. Widlund HR, Kuduvalli PN, Bengtsson M, Cao H, Tullius TD, Kubista M: Nucleosome structural features and intrinsic properties of the TATAAACGCC repeat sequence. J Biol Chem 1999, 274(45):31847-31852.

21. Thastrom A, Lowary PT, Widlund HR, Cao H, Kubista M, Widom J: Sequence motifs and free energies of selected natural and non-natural nucleosome positioning DNA sequences. J Mol Biol 1999, 288(2):213-229.

22. Cao H, Widlund HR, Simonsson T, Kubista M: TGGA repeats impair nucleosome formation. J Mol Biol 1998, 281(2):253-260.

23. Widlund HR, Cao H, Simonsson S, Magnusson E, Simonsson T, Nielsen PE, Kahn JD, Crothers DM, Kubista M: Identification and characterization of genomic nucleosome-positioning sequences. J Mol Biol 1997, 267(4):807-817.